These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Development of gene therapy for treatment of age-related macular degeneration. Askou AL Acta Ophthalmol; 2014 Jul; 92 Thesis3():1-38. PubMed ID: 24953666 [TBL] [Abstract][Full Text] [Related]
6. Emerging Concepts for RNA Therapeutics for Inherited Retinal Disease. Moore SM; Skowronska-Krawczyk D; Chao DL Adv Exp Med Biol; 2019; 1185():85-89. PubMed ID: 31884593 [TBL] [Abstract][Full Text] [Related]
7. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Singh S; Narang AS; Mahato RI Pharm Res; 2011 Dec; 28(12):2996-3015. PubMed ID: 22033880 [TBL] [Abstract][Full Text] [Related]
8. Liver as a target for oligonucleotide therapeutics. Sehgal A; Vaishnaw A; Fitzgerald K J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039 [TBL] [Abstract][Full Text] [Related]
9. RNA interference silencing the transcriptional message: aspects and applications. Karkare S; Daniel S; Bhatnagar D Appl Biochem Biotechnol; 2004 Oct; 119(1):1-12. PubMed ID: 15496724 [TBL] [Abstract][Full Text] [Related]
10. RNAi in clinical studies. Kubowicz P; Żelaszczyk D; Pękala E Curr Med Chem; 2013; 20(14):1801-16. PubMed ID: 23432579 [TBL] [Abstract][Full Text] [Related]
11. In vivo application of RNA interference: from functional genomics to therapeutics. Lu PY; Xie F; Woodle MC Adv Genet; 2005; 54():117-42. PubMed ID: 16096010 [TBL] [Abstract][Full Text] [Related]
12. [Great potential of small RNAs: RNA interference and microRNA]. Vázquez-Ortiz G; Piña-Sánchez P; Salcedo M Rev Invest Clin; 2006; 58(4):335-49. PubMed ID: 17146945 [TBL] [Abstract][Full Text] [Related]
13. miRNA and shRNA expression vectors based on mRNA and miRNA processing. Wu P; Wilmarth MA; Zhang F; Du G Methods Mol Biol; 2013; 936():195-207. PubMed ID: 23007510 [TBL] [Abstract][Full Text] [Related]
14. RNA therapeutics: Identification of novel targets leading to drug discovery. Qadir MI; Bukhat S; Rasul S; Manzoor H; Manzoor M J Cell Biochem; 2020 Feb; 121(2):898-929. PubMed ID: 31478252 [TBL] [Abstract][Full Text] [Related]
15. Target binding triggers hierarchical phosphorylation of human Argonaute-2 to promote target release. Bibel B; Elkayam E; Silletti S; Komives EA; Joshua-Tor L Elife; 2022 May; 11():. PubMed ID: 35638597 [TBL] [Abstract][Full Text] [Related]
16. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases. Holm A; Hansen SN; Klitgaard H; Kauppinen S RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908 [TBL] [Abstract][Full Text] [Related]
17. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity. Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271 [TBL] [Abstract][Full Text] [Related]
18. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Pandey M; Ojha D; Bansal S; Rode AB; Chawla G Mol Aspects Med; 2021 Oct; 81():101003. PubMed ID: 34332771 [TBL] [Abstract][Full Text] [Related]
19. RNA silencing and HIV: a hypothesis for the etiology of the severe combined immunodeficiency induced by the virus. Ludwig LB Retrovirology; 2008 Sep; 5():79. PubMed ID: 18786256 [TBL] [Abstract][Full Text] [Related]
20. RNA interference and cancer therapy. Wang Z; Rao DD; Senzer N; Nemunaitis J Pharm Res; 2011 Dec; 28(12):2983-95. PubMed ID: 22009588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]